Y-Intercept (HK)’s Corcept Therapeutics CORT Stock Holding History

Y-Intercept (HK)’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.77M	Buy	+41,424	New	+$4.46M	0.11%	248
2025 Q4	–	Sell	-35,901	Closed	-$2.98M	–	1615
2025 Q3	$2.98M	Buy	35,901 +15,033	+72%	+$1.09M	0.07%	407
2025 Q2	$1.53M	Buy	20,868 +11,881	+132%	+$861K	0.04%	727
2025 Q1	$1.03M	Sell	8,987 -33,031	-79%	-$2.01M	0.07%	398
2024 Q4	$2.12M	Buy	+42,018	New	+$2.2M	0.14%	194
2023 Q4	–	Sell	-7,765	Closed	-$212K	–	1282
2023 Q3	$212K	Buy	+7,765	New	+$225K	0.02%	897
2023 Q1	–	Sell	-11,139	Closed	-$226K	–	1229
2022 Q4	$226K	Buy	+11,139	New	+$279K	0.03%	781
2022 Q2	–	Sell	-11,782	Closed	-$265K	–	906
2022 Q1	$265K	Buy	+11,782	New	+$251K	0.06%	500

Other funds holding CORT

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Y-Intercept (HK)'s CORT Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 41,424 shares worth $4.77M. The stake represents 0.11% of the portfolio and ranks #248 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CORT as recently as Q3 2025.

Y-Intercept (HK) first reported a position in CORT in Q1 2022 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Y-Intercept (HK) held 41,424 shares of Corcept Therapeutics worth $4.77M as of Q3 2026.
Corcept Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
Corcept Therapeutics made up 0.11% of Y-Intercept (HK)'s portfolio in Q3 2026, its #248 holding.
Y-Intercept (HK) first reported a position in Corcept Therapeutics in Q1 2022 and has held it in 8 quarters since.
265 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.